[Report from an international consensus conference in Maastricht. Management and treatment of Helicobacter pylori infection].
Sjölund
K
K
Gastrosektionen, Universitetssjukhuset, Lund samt numera Astra Zeneca. Kristina.Sjolund@med.lu.se
Ljungh
A
A
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D003245:Consensus Statements as Topic; D004415:Dyspepsia / Q000188:drug therapy / Q000382:microbiology; D005243:Feces / Q000382:microbiology; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000382:microbiology; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D009426:Netherlands; D017410:Practice Guidelines as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D013276:Stomach Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents